Akèy › Sistèm Imunitè ak Twoub › New York › New York City
Etid klinik pou Sistèm Imunitè ak Twoub nan New York City, NY
12 etid pou Sistèm Imunitè ak Twoub ap chèche patisipan nan sit nan ak bò kote New York City (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
Ap rekriteFaz 1
- Memorial Sloan Kettering Cancer Center, New York
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Ap rekriteFaz 3
- Memorial Sloan Kettering Cancer Center, New York
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Ap rekriteFaz 3
- Memorial Sloan Kettering Cancer Center, New York
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Ap rekriteFaz 1/2
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
Abatacept for the Treatment of Giant Cell Arteritis
Ap rekriteFaz 3
- Hospital for Special Surgery, New York
Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
Ap rekriteFaz 3
- Icahn School of Medicine at Mount Sinai, New York
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
Ap rekriteFaz 2
- Inmagene Site 21, New York
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Ap rekriteFaz 2
- Weill Cornell Medicine - New York Presbyterian Hospital, New York
A Study of Treatment of Inflammation Before Stem Cell Transplant in People With a Primary Immune Regulatory Disorder (PIRD) and/or an Autoinflammatory Condition
Ap rekriteFaz 2
- Columbia University Irving Medical Center, New York
A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
Ap rekriteFaz 1/2
- Columbia University, New York
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Ap rekriteFaz 1/2
- Mt Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
Biologics And Clinical Immunology Cohort at Sinai
Ap rekriteEtid obsèvasyon
- Mount Sinai, New York
Etid Sistèm Imunitè ak Twoub nan lòt vil
- Washington, DC13 etid
- Philadelphia, PA10 etid
- Boston, MA10 etid
- Portland, OR9 etid
- Atlanta, GA9 etid
- Houston, TX9 etid
- Cleveland, OH8 etid
- Chicago, IL8 etid
- Los Angeles, CA8 etid
- Milwaukee, WI6 etid
- Seattle, WA6 etid
- Cedar Rapids, IA6 etid
Lòt etid nan New York City
- Kansè nan tete136 etid
- Kansè Poumon ki pa ti selil121 etid
- Kansè (tout kalite)109 etid
- Kansè pwostat103 etid
- Kansè Metastatik93 etid
- Kansè kolorektal78 etid
- Kansè ovè69 etid
- Kansè poumon60 etid
- Myelom Miltip60 etid
- Kansè pankreyas60 etid
- Kansè Endomèt52 etid
- Leksemi mieloïd egi51 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.